GlassScriptPhysician profile
Ashley Biondo
NPI 1902381858
$10,097.23
in general payments reported to CMS, 2019-2025
21 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,029 · 2022: $1,818 · 2023: $1,609 · 2024: $1,539 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,244.28 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,582.83 | 2021-2025 | |
| Glaxosmithkline, LLC. | $2,086.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $1,063.29 | 2022-2025 | Apretude |
| Biohaven Pharmaceuticals, INC. | $920.89 | 2021 | |
| Lundbeck LLC | $594.84 | 2022-2025 | Rexulti, Vyepti |
| Pfizer INC. | $523.40 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $432.95 | 2023-2024 | Quviviq |
| Gilead Sciences, INC. | $397.44 | 2022-2025 | Yeztugo |
| Astrazeneca Pharmaceuticals LP | $367.95 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $276.52 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $254.43 | 2021-2023 | Trintellix |
| Genzyme Corporation | $158.80 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.40 | 2022 | |
| Eisai INC. | $80.72 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.78 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $37.06 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Hologic Sales and Service, LLC | $24.80 | 2025 | Aptima |
| Bausch Health US, LLC | $24.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.16 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $17.82 | 2023 | |
| Covis Pharma Gmbh | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Biondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.